Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Wearable medical devices are changing healthcare delivery by shifting care beyond traditional settings and bringing it closer to patients’ daily lives. By offering continuous monitoring, promoting patient engagement and supporting remote interventions, these technologies are becoming an essential part of…
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us